Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans

about

A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations(5633).Efficacy of levomilnacipran extended release in treating major depressive disorder.

P2860

Q38770060-2516BDA3-DAFF-4E2D-B781-BF54207208CF Q47303967-79243548-618B-483C-98E1-6C3FA2EE819D

P2860

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans

Item

http://www.wikidata.org/entity/Q35799145

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Effect of renal impairment on ...... nded-release capsule in humans

@ast

Effect of renal impairment on ...... nded-release capsule in humans

@en

type

Item

label

Effect of renal impairment on ...... nded-release capsule in humans

@ast

Effect of renal impairment on ...... nded-release capsule in humans

@en

prefLabel

Effect of renal impairment on ...... nded-release capsule in humans

@ast

Effect of renal impairment on ...... nded-release capsule in humans

@en

P1476

Effect of renal impairment on ...... nded-release capsule in humans

@en

P2093

Antonia Periclou

http://www.w3.org/2001/XMLSchema#string

Elimor Brand-Schieber

http://www.w3.org/2001/XMLSchema#string

Julie Wangsa

http://www.w3.org/2001/XMLSchema#string

Laishun Chen

http://www.w3.org/2001/XMLSchema#string

Parviz Ghahramani

http://www.w3.org/2001/XMLSchema#string

William M Greenberg

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder

Prediction of creatinine clearance from serum creatinine

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.

A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.

Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.

Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.

Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants.

P304

3293-3300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S85418

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26150701

http://www.w3.org/2001/XMLSchema#string

P932

4485797

http://www.w3.org/2001/XMLSchema#string

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans

about

P2860

P2860

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932